Amy E. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amy E. Smith has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Alisa Kane
Department of Immunology and HIV, St Vincent's Hospital, Sydney, NSW, Australia
1 shared publication- Arjun Muralidharan
Charles Perkin Centre, Faculty of Science, University of Sydney, New South Wales, Australia
1 shared publication - Catherine Krejany
Melbourne Clinical School, School of Medicine Sydney, University of Notre Dame Australia, Werribee, Australia
1 shared publication Catriona McNeil
Department of Medical Oncology, Chris O’Brien Lifehouse, Sydney, Australia
1 shared publicationFlorian Honeyball
Western Cancer Centre Dubbo Base Hospital Dubbo Australia
1 shared publication- Florian Honeyball
Western Cancer Centre, Dubbo Base Hospital, Dubbo, Australia; School of Rural Health, University of Sydney, Sydney, Australia
1 shared publication
Latest Publications
- 2 October 2025
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 22 (2) , 288-295
Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network
Background: Imatinib for palliative and adjuvant treatment of gastrointestinal stromal tumours (GISTs) with common KIT mutations has been revolutionary. For patients with locally advanced, limited metastatic or recurrent disease, neoadjuvant imatinib may downstage the tumour, enabling surgery with curative intent; however, the optimal duration of neoadjuvant imatinib is unknown. Methods: We conducted a retrospective review of patients with locally advanced, limited metastatic and recurrent GIST treated with neoadjuvant imatinib prior to consideration of surgical resection in the period 2012–2024 at three cancer centres in NSW, Australia. Baseline and outcome data were collected. The primary endpoint was the progression‐free survival (PFS). Results: A total of 30 patients were identified with 38 instances of primary locally advanced, recurrent or limited metastatic disease. The median per‐patient duration of neoadjuvant imatinib was 7.8 months (range 2.9–14.9 months), and the median per‐episode duration of neoadjuvant imatinib was 9.1 months (range 3.0–27.4 months). Maximum radiological response was achieved at 3.8 months for primary tumours and 6.7 months for recurrent tumours. Partial response occurred in 77% and progression in 0%. Of the 25 patients with available data, 96% were symptomatic, and 89% reported early symptomatic benefit from imatinib within 1 month. Complete surgical resection occurred in 58% of all episodes of neoadjuvant treatment. The estimated PFS rates at 2 and 5 years were 84% and 55% respectively. Overall survival rates were 84% at both 2 and 5 years. Conclusions: Neoadjuvant imatinib provided effective symptomatic and radiological responses in patients with locally advanced, limited metastatic or recurrent GIST. A duration of 3–6 months treatment for primary tumours and 6–12 months for recurrent disease appears sufficient for most patients. Mutational profile analysis is of particular value for patients who do not have early symptomatic benefit, have poor radiological response or have recurrent disease.
- 2 October 2025
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 22 (2) , 288-295
Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network
Background: Imatinib for palliative and adjuvant treatment of gastrointestinal stromal tumours (GISTs) with common KIT mutations has been revolutionary. For patients with locally advanced, limited metastatic or recurrent disease, neoadjuvant imatinib may downstage the tumour, enabling surgery with curative intent; however, the optimal duration of neoadjuvant imatinib is unknown. Methods: We conducted a retrospective review of patients with locally advanced, limited metastatic and recurrent GIST treated with neoadjuvant imatinib prior to consideration of surgical resection in the period 2012–2024 at three cancer centres in NSW, Australia. Baseline and outcome data were collected. The primary endpoint was the progression‐free survival (PFS). Results: A total of 30 patients were identified with 38 instances of primary locally advanced, recurrent or limited metastatic disease. The median per‐patient duration of neoadjuvant imatinib was 7.8 months (range 2.9–14.9 months), and the median per‐episode duration of neoadjuvant imatinib was 9.1 months (range 3.0–27.4 months). Maximum radiological response was achieved at 3.8 months for primary tumours and 6.7 months for recurrent tumours. Partial response occurred in 77% and progression in 0%. Of the 25 patients with available data, 96% were symptomatic, and 89% reported early symptomatic benefit from imatinib within 1 month. Complete surgical resection occurred in 58% of all episodes of neoadjuvant treatment. The estimated PFS rates at 2 and 5 years were 84% and 55% respectively. Overall survival rates were 84% at both 2 and 5 years. Conclusions: Neoadjuvant imatinib provided effective symptomatic and radiological responses in patients with locally advanced, limited metastatic or recurrent GIST. A duration of 3–6 months treatment for primary tumours and 6–12 months for recurrent disease appears sufficient for most patients. Mutational profile analysis is of particular value for patients who do not have early symptomatic benefit, have poor radiological response or have recurrent disease.
- Open Access
- 30 June 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-5
Parotid Metastasis 10 Years After Initial Diagnosis of HER2 Positive Breast Cancer: A Case Report
The parotid gland is a rare site of metastatic disease in human epidermal growth factor receptor 2 (HER2) positive breast cancer. It often presents as a painless enlarging mass at the angle of the jaw; however, rarely it can be associated with facial nerve palsy. There is no consensus regarding the best approach to managing these uncommon metastases. We report the case of a patient with metastatic HER2 positive breast cancer who developed oligoprogressive disease with a parotid metastasis over 10 years after initial diagnosis of metastatic disease. There are only 5 reported cases of HER2 positive breast cancer with parotid metastases. Our patient underwent treatment with palliative radiotherapy, followed by the continuation of her HER2 targeted systemic therapy with good effect. This case is significant due to the lengthy period (10 years) after initial diagnosis that the metastasis appeared, the treatment the patient received for it (radiation) and the available overall survival and progression-free survival data from time of parotid metastasis diagnosis.
- 30 June 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-5
Open AccessParotid Metastasis 10 Years After Initial Diagnosis of HER2 Positive Breast Cancer: A Case Report
The parotid gland is a rare site of metastatic disease in human epidermal growth factor receptor 2 (HER2) positive breast cancer. It often presents as a painless enlarging mass at the angle of the jaw; however, rarely it can be associated with facial nerve palsy. There is no consensus regarding the best approach to managing these uncommon metastases. We report the case of a patient with metastatic HER2 positive breast cancer who developed oligoprogressive disease with a parotid metastasis over 10 years after initial diagnosis of metastatic disease. There are only 5 reported cases of HER2 positive breast cancer with parotid metastases. Our patient underwent treatment with palliative radiotherapy, followed by the continuation of her HER2 targeted systemic therapy with good effect. This case is significant due to the lengthy period (10 years) after initial diagnosis that the metastasis appeared, the treatment the patient received for it (radiation) and the available overall survival and progression-free survival data from time of parotid metastasis diagnosis.
- Open Access
- 23 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (7) , 1-6
Assessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: a cross-sectional survey
Background: Alopecia is a distressing side-effect of taxane chemotherapy, and evidence suggests that docetaxel leads to chronic alopecia. We measured rates of satisfaction with hair regrowth among women who received adjuvant docetaxel compared with paclitaxel to identify a difference in outcomes. Methods: We identified adult female patients who received paclitaxel or docetaxel chemotherapy for early breast cancer from 2010 to 2015. They were screened to ensure they were alive, without metastatic relapse or a new cancer. Eligible participants were sent an introductory letter, consent, a Dermatology Life Quality Index (DLQI) questionnaire, a Visual Analogue Score (VAS) and the European Organisation for Research and Treatment of Cancer (EORTC) general and breast-specific quality of life. The primary outcomes were the DLQI: a 10-item questionnaire scored on a 0–3 scale (higher scores indicating distress and dissatisfaction) and the VAS (scored out of 4). Secondary outcomes were the global health status, function, symptom score and breast specific outcomes shown by the EORTC QLQ-C30 and EORTC QLQ-BR23. Results: There were 88 responders from 210 letters (response rate 42%); 38 (43%) had docetaxel and 50 (57%) had paclitaxel. They were aged 26–90 (median: 59). There was a significant difference in DLQI scores, with the docetaxel group having a higher median score (docetaxel: 4 vs paclitaxel: 1, p = 0.01). A significantly higher proportion of patients reported no effect of hair loss in the paclitaxel group (p = 0.02). Similarly, there was a significant difference in VAS scores with the docetaxel group having a higher median score (docetaxel: 1 vs. paclitaxel: 0.5, p = 0.002). Secondary outcomes did not reach statistical significance. There was no association with aromatase inhibitor exposure. Conclusions: Our study shows that adjuvant docetaxel chemotherapy is associated with statistically significant higher rates of dissatisfaction and chronic alopecia than paclitaxel chemotherapy. This supports literature and should be discussed prior to administering docetaxel regimens.
- 23 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (7) , 1-6
Open AccessAssessment of long-term alopecia after adjuvant taxane therapy for early breast cancer: a cross-sectional survey
Background: Alopecia is a distressing side-effect of taxane chemotherapy, and evidence suggests that docetaxel leads to chronic alopecia. We measured rates of satisfaction with hair regrowth among women who received adjuvant docetaxel compared with paclitaxel to identify a difference in outcomes. Methods: We identified adult female patients who received paclitaxel or docetaxel chemotherapy for early breast cancer from 2010 to 2015. They were screened to ensure they were alive, without metastatic relapse or a new cancer. Eligible participants were sent an introductory letter, consent, a Dermatology Life Quality Index (DLQI) questionnaire, a Visual Analogue Score (VAS) and the European Organisation for Research and Treatment of Cancer (EORTC) general and breast-specific quality of life. The primary outcomes were the DLQI: a 10-item questionnaire scored on a 0–3 scale (higher scores indicating distress and dissatisfaction) and the VAS (scored out of 4). Secondary outcomes were the global health status, function, symptom score and breast specific outcomes shown by the EORTC QLQ-C30 and EORTC QLQ-BR23. Results: There were 88 responders from 210 letters (response rate 42%); 38 (43%) had docetaxel and 50 (57%) had paclitaxel. They were aged 26–90 (median: 59). There was a significant difference in DLQI scores, with the docetaxel group having a higher median score (docetaxel: 4 vs paclitaxel: 1, p = 0.01). A significantly higher proportion of patients reported no effect of hair loss in the paclitaxel group (p = 0.02). Similarly, there was a significant difference in VAS scores with the docetaxel group having a higher median score (docetaxel: 1 vs. paclitaxel: 0.5, p = 0.002). Secondary outcomes did not reach statistical significance. There was no association with aromatase inhibitor exposure. Conclusions: Our study shows that adjuvant docetaxel chemotherapy is associated with statistically significant higher rates of dissatisfaction and chronic alopecia than paclitaxel chemotherapy. This supports literature and should be discussed prior to administering docetaxel regimens.
- Open Access
- 22 April 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (4) , 102365
Review of Relapse Detection Methods in Stage 1 Testicular Germ Cell Tumors in Patients After Orchidectomy Managed With Active Surveillance: Is Physical Examination Required?
- 22 April 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (4) , 102365
Open AccessReview of Relapse Detection Methods in Stage 1 Testicular Germ Cell Tumors in Patients After Orchidectomy Managed With Active Surveillance: Is Physical Examination Required?
- Open Access
- 28 February 2023
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 122-129
Two Very Rare Cases of Metastatic Thymic Carcinoma with Sjogren’s Syndrome: A Case Series
Thymic tumours are rare thoracic malignancies with thymic carcinoma accounting for approximately 12% of all thymic tumours compared to thymomas which account for approximately 86%. Unlike thymomas, it is very rare for thymic carcinomas to be associated with autoimmune disorders or paraneoplastic syndromes. When these phenomena do occur, the vast majority are myasthenia gravis, pure red cell aplasia, or systemic lupus erythematous. Paraneoplastic Sjogren’s syndrome is a rare complication of thymic carcinoma, with only two cases previously reported. Here we present 2 cases of patients with metastatic thymic carcinoma who developed autoimmune phenomena consistent with Sjogren’s syndrome without classical symptoms prior to treatment. One patient opted for surveillance of their malignancy, while the other underwent chemoimmunotherapy with favourable results. These case reports describe two distinctive clinical presentations of a rare paraneoplastic phenomenon.
- 28 February 2023
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 122-129
Open AccessTwo Very Rare Cases of Metastatic Thymic Carcinoma with Sjogren’s Syndrome: A Case Series
Thymic tumours are rare thoracic malignancies with thymic carcinoma accounting for approximately 12% of all thymic tumours compared to thymomas which account for approximately 86%. Unlike thymomas, it is very rare for thymic carcinomas to be associated with autoimmune disorders or paraneoplastic syndromes. When these phenomena do occur, the vast majority are myasthenia gravis, pure red cell aplasia, or systemic lupus erythematous. Paraneoplastic Sjogren’s syndrome is a rare complication of thymic carcinoma, with only two cases previously reported. Here we present 2 cases of patients with metastatic thymic carcinoma who developed autoimmune phenomena consistent with Sjogren’s syndrome without classical symptoms prior to treatment. One patient opted for surveillance of their malignancy, while the other underwent chemoimmunotherapy with favourable results. These case reports describe two distinctive clinical presentations of a rare paraneoplastic phenomenon.
- Open Access
- 18 October 2022
- Published by Springer Nature in Discover Oncology
- Vol. 13 (1) , 1-23
Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials
Purpose: Metastatic spread of prostate cancer to the skeleton may result in debilitating bone pain. In this review, we address mechanisms underpinning the pathobiology of metastatic prostate cancer induced bone pain (PCIBP) that include sensitization and sprouting of primary afferent sensory nerve fibres in bone. We also review current treatments and pain responses evoked by various treatment modalities in clinical trials in this patient population. Methods: We reviewed the literature using PubMed to identify research on the pathobiology of PCIBP. Additionally, we reviewed clinical trials of various treatment modalities in patients with PCIBP with pain response outcomes published in the past 7 years. Results: Recent clinical trials show that radionuclides, given either alone or in combination with chemotherapy, evoked favourable pain responses in many patients and a single fraction of local external beam radiation therapy was as effective as multiple fractions. However, treatment with chemotherapy, small molecule inhibitors and/or immunotherapy agents, produced variable pain responses but pain response was the primary endpoint in only one of these trials. Additionally, there were no published trials of potentially novel analgesic agents in patients with PCIBP. Conclusion: There is a knowledge gap for clinical trials of chemotherapy, small molecule inhibitors and/or immunotherapy in patients with PCIBP where pain response is the primary endpoint. Also, there are no novel analgesic agents on the horizon for the relief of PCIBP and this is an area of large unmet medical need that warrants concerted research attention.
- 18 October 2022
- Published by Springer Nature in Discover Oncology
- Vol. 13 (1) , 1-23
Open AccessProstate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials
Purpose: Metastatic spread of prostate cancer to the skeleton may result in debilitating bone pain. In this review, we address mechanisms underpinning the pathobiology of metastatic prostate cancer induced bone pain (PCIBP) that include sensitization and sprouting of primary afferent sensory nerve fibres in bone. We also review current treatments and pain responses evoked by various treatment modalities in clinical trials in this patient population. Methods: We reviewed the literature using PubMed to identify research on the pathobiology of PCIBP. Additionally, we reviewed clinical trials of various treatment modalities in patients with PCIBP with pain response outcomes published in the past 7 years. Results: Recent clinical trials show that radionuclides, given either alone or in combination with chemotherapy, evoked favourable pain responses in many patients and a single fraction of local external beam radiation therapy was as effective as multiple fractions. However, treatment with chemotherapy, small molecule inhibitors and/or immunotherapy agents, produced variable pain responses but pain response was the primary endpoint in only one of these trials. Additionally, there were no published trials of potentially novel analgesic agents in patients with PCIBP. Conclusion: There is a knowledge gap for clinical trials of chemotherapy, small molecule inhibitors and/or immunotherapy in patients with PCIBP where pain response is the primary endpoint. Also, there are no novel analgesic agents on the horizon for the relief of PCIBP and this is an area of large unmet medical need that warrants concerted research attention.
- 20 August 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (1) , 46-51
Epidemiology of soccer‐related head injury in children 5–14 years in Victoria, Australia
Aim: Our aim was to use epidemiological data to determine the incidence of soccer‐related head injuries in children aged 5–14 years who presented at emergency departments (EDs) or were admitted in hospitals in Victoria, Australia.Methods: ED presentation and hospital admission de‐identified aggregate data were from the Victorian Injury Surveillance Unit. Soccer participation data were compared with the soccer‐related head injury data to determine the incidence of this injury among these children.Results: The incidence of ED presentations was 0.17% of children participating in soccer during the study period (financial years 2011–2012 to 2015–2016). The 10–14‐years age group presented with more head injuries than the 5–9‐years age group. For the admissions data, soccer had a significantly lower (P = 0.0379) incidence of head injury when compared with ‘sport as a whole’.Conclusions: The low incidence of soccer‐related head injuries presenting to an ED or admission to hospital is consistent with international findings.
- 20 August 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (1) , 46-51
Epidemiology of soccer‐related head injury in children 5–14 years in Victoria, Australia
Aim: Our aim was to use epidemiological data to determine the incidence of soccer‐related head injuries in children aged 5–14 years who presented at emergency departments (EDs) or were admitted in hospitals in Victoria, Australia.Methods: ED presentation and hospital admission de‐identified aggregate data were from the Victorian Injury Surveillance Unit. Soccer participation data were compared with the soccer‐related head injury data to determine the incidence of this injury among these children.Results: The incidence of ED presentations was 0.17% of children participating in soccer during the study period (financial years 2011–2012 to 2015–2016). The 10–14‐years age group presented with more head injuries than the 5–9‐years age group. For the admissions data, soccer had a significantly lower (P = 0.0379) incidence of head injury when compared with ‘sport as a whole’.Conclusions: The low incidence of soccer‐related head injuries presenting to an ED or admission to hospital is consistent with international findings.